Prediction of response to platinum-based therapy

US8747910B2 · kind B2 · utility

Assignee

• Atlas Antibodies AB · SE

Inventors

• Karin Jirström · Malmö, SE
• Jakob Eberhard · Lund, SE

Key dates

• Filing date: Feb 16, 2010
• Grant date: Jun 10, 2014
• Expiry date: Feb 16, 2030

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N33/5743
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Method for determining whether a mammalian subject having a cancer belongs to a first or a second group, wherein subjects of the first group are more likely to respond to a platinum-based therapy than subjects of the second group, comprising the steps of: evaluating the amount of RBM3 protein or RBM3 mRNA present in at least part of a sample earlier obtained from said subject, and determining a sample value corresponding to said amount; comparing the sample value with a reference value; and, if said sample value is higher than said reference value, concluding that said subject belongs to a first group; and if said sample value is lower than or equal to said reference value, concluding that said subject belongs to a second group. There is further provided means useful in the establishment of a treatment prediction.